Ignite Creation Date:
2024-05-06 @ 2:28 PM
Last Modification Date:
2024-10-26 @ 1:31 PM
Study NCT ID:
NCT04323436
Status:
TERMINATED
Last Update Posted:
2024-02-06
First Post:
2020-03-23
Brief Title:
Study of Capmatinib and SpartalizumabPlacebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Organization Data
Organization:
Novartis
Class:
INDUSTRY
Study ID:
CINC280J12201
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Novartis Pharmaceuticals
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None